Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2014

Filing Date
Filed February 9, 2015
Period End
December 31, 2014
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 9, 2015. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported in its 10-K for fiscal 2014 that it has not generated any revenue from product sales and remains a clinical-stage company.

Its two lead late-stage programs are elagolix, a GnRH antagonist for endometriosis and uterine fibroids partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor (NBI-98854) for tardive dyskinesia, which is in Phase III. The company also advanced a CRF1 antagonist (NBI-77860) for classic congenital adrenal hyperplasia into clinical development in 2014. Total revenues were zero in 2014, compared with $2.9 milliona in 2013 and $53.1 million in 2012, while operating expenses rose to $64.4 million from $52.6 million, driven by higher research and development expense of $46.4 million and general and administrative expense of $18.0 million.

The net loss widened to $60.5 millionb, or $0.81 per share, from $46.1 million, or $0.69 per share. The balance sheet strengthened over the year. Cash, cash equivalents and investments totaled $231.3 million at December 31, 2014, up from $145.7 million, after a February 2014 public offering of 8.0 million shares that netted approximately $133.2 million.

The company reports no outstanding debt and an accumulated deficit of $826.3 millionc. Management states that existing capital resources, investment income and future alliance payments will be sufficient for at least the next 12 months, and it expects a net loss and higher expenses in 2015 as VMAT2 Phase III development and the CAH program advance and commercial preparation for tardive dyskinesia begins.

Key pipeline milestones cited in the filing include AbbVie's Violet PETAL Phase III elagolix results (announced January 8, 2015, with both doses meeting co-primary endpoints at months three and six), top-line Kinect 3 data for NBI-98854 expected in the second half of 2015, and the FDA's breakthrough therapy designation for NBI-98854 in tardive dyskinesia granted in October 2014. The company had 94 full-time employees at December 31, 2014 and is not a party to any material legal proceedings.

Key Highlights

  1. No product revenue: total revenues were $0 in 2014, versus $2.9 million in 2013 and $53.1 million in 2012, as prior AbbVie and Boehringer Ingelheim collaboration revenue ended.
  2. Net loss widened to $60.5 million ($0.81 per share) in 2014 from $46.1 million ($0.69 per share) in 2013, as operating expenses rose to $64.4 million.
  3. R&D expense rose to $46.4 million from $39.2 million, driven by personnel costs and the new CRF program; G&A rose to $18.0 million from $13.3 million.
  4. Cash, cash equivalents and investments were $231.3 million at year-end 2014, up from $145.7 million, following a February 2014 offering that netted about $133.2 million; the company reports no debt.
  5. Lead programs: elagolix (partnered with AbbVie) is in Phase III for endometriosis, and NBI-98854 (VMAT2 inhibitor) is in Phase III for tardive dyskinesia, with breakthrough therapy designation granted in October 2014.
  6. AbbVie's Violet PETAL Phase III for elagolix met both co-primary endpoints at months three and six (top-line results announced January 8, 2015); the one-year dosing portion is expected to conclude in May 2015.
  7. Management expects a net loss in 2015 and a significant increase in R&D and G&A expenses, and states capital resources are sufficient for at least the next 12 months.

Financial Statements

FY2014 against FY2013

Line itemFY2014FY2013Change
Revenue$0$2.92M−100.0%
R&D Expenses$46.42M$39.25M+18.3%
Operating Expenses$64.41M$52.60M+22.5%
Operating Income-$64.41M-$49.68M−29.7%
Net Income-$60.54M-$46.09M−31.4%
EPS (Basic)$-0.81$-0.69−17.4%
EPS (Diluted)$-0.81$-0.69−17.4%
Shares Outstanding (Basic)74.58M66.99M+11.3%
Shares Outstanding (Diluted)74.58M66.99M+11.3%

Frequently Asked Questions

  1. Does Neurocrine currently generate revenue from product sales?

    No. The filing states that the company has not generated any revenues from the sale of products and has not yet obtained regulatory approval for any product. Revenue in 2014 was zero, and prior revenue came from collaboration agreements that concluded in 2012 and 2013.

  2. How much cash does the company have, and is it raising additional capital?

    Cash, cash equivalents and investments totaled $231.3 million at December 31, 2014. The company completed an 8.0 million share public offering in February 2014 with net proceeds of about $133.2 million. It has no outstanding debt and states that existing resources are sufficient for at least the next 12 months, while noting it may seek additional funding through equity or alliances.

  3. What are the most important near-term catalysts described in the filing?

    The filing cites AbbVie's Violet PETAL Phase III elagolix results (with the one-year portion expected to conclude in May 2015), top-line efficacy data from the Kinect 3 Phase III study of NBI-98854 in tardive dyskinesia expected in the second half of 2015, the Solstice Phase III elagolix study with results expected in late 2015, and a planned New Drug Application for tardive dyskinesia in 2016.

  4. Why are losses expected to grow in 2015?

    The company expects higher R&D expense as the VMAT2 inhibitor advances in Phase III and the congenital adrenal hyperplasia program is added, plus higher G&A from pre-commercialization activities for tardive dyskinesia and higher share-based compensation tied to Black-Scholes valuations and anticipated vesting of performance-based restricted stock units.

  5. What is the status of the company's collaboration with AbbVie?

    AbbVie holds worldwide development and commercialization rights to elagolix and next-generation GnRH antagonists for women's and men's health, and is responsible for development, marketing and commercialization costs. The company is entitled to a percentage of worldwide sales. The filing notes $500 million in future event-based payments remain outstanding, and that AbbVie may terminate the collaboration on 180 days' notice.